FindTrial
Sign In

A Single-Blinded, Randomized, Split-Face Study of Efficacy and Safety Using Low-Fluence Q-Switched Nd:YAG 1064 nm Compared to Fractional Picosecond Nd:YAG 532 nm in the Treatment of Melasma

A Single-Blinded, Randomized, Split-Face Study of Efficacy and Safety Using Low-Fluence Q-Switched Nd:YAG 1064 nm Compared to Fractional Picosecond Nd:YAG 532 nm in the Treatment of Melasma

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20171130002
Enrollment
Unknown
Registered
2017-11-30
Start date
2017-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma&#44

Interventions

Fractional picosecond Nd:YAG 532 nm by Discovery PICO&#44
Quanta&#44
Italy Parameter : ,Low&#45
fluence Q&#45
Switched Nd:YAG 1064 nm by RevLite(®)
HOYA ConBio(®)&#44
Freemont&#44
CA&#44
USA Parameter :
Experimental Device,Active Comparator Device
Fractional picosecond Nd:YAG 532 nm,Low&#45
Switched Nd:YAG 1064 nm

Sponsors

Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol U
Lead Sponsor
Mahidol University
Collaborator

Eligibility

Sex/Gender
All
Age
0 Years to 0 Years

Inclusion criteria

Inclusion criteria: 1. Age over 18 year-old 2. Presence of all types of melasma on both sides of face 3. Compatible with follow-up and treatment schedule 4. Informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnancy or on lactation periodตั้งครรภ์ ให้นมบุตร 2. Receiving oral contraception or replacement hormonal therapy within 1 year 3. Previously treated with energy-based devices within 1 months (for melasma) 4. Previously treated with topical anti-melasma or bleaching agents within 1 month 5. Presence of underlying autoimmune disorders 6. Presence of wound or severe cystic acne on face 7. Presence of pre-existing facial skin conditions 8. Severe underlying diseases 9. History of photo allergy 9. Withdraw

Design outcomes

Primary

MeasureTime frame
mMASI (modified Melasma Area and Severity Index) Week 0, Week 2, Week 4, Week 6, Week 10, Week 14, Week 18 Photos taken with VISIA and evaluated by blinded dermatologists,Melanin index Week 0, Week 2, Week 4, Week 6, Week 10, Week 14, Week 18 Chromameter CR-200 Panasonic,Improvement score Week 10, Week 14, Week 18 Rating scale by blinded dermatologists and patients—

Secondary

MeasureTime frame
Adverse effects Week 0, Week 2, Week 4, Week 6, Week 10, Week 14, Week 18 Evaluated from patients and attending dermatologists,Patient satisfaction Week 10, Week 14, Week 18 Patients satisfaction rating score,Pain score Week 0, Week 2, Week 4, Week 6 Visual analogue scale—

Countries

Thailand

Contacts

Public ContactSarawin Harnchoowong

Division of Dermatology, Faculty of Medicine Ramathibodi Hospital

hsarawin@gmail.com6622011211

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026